MedTrace Logo

Intermittent Preventive Treatment With Antimalarials in Kenyan Infants

NCT00111163 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1516

Last updated 2012-09-27

No results posted yet for this study

Summary

The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.

Conditions

Interventions

DRUG

sulfadoxine-pyrimethamine with artesunate

DRUG

amodiaquine with artesunate

DRUG

chlorproguanil-dapsone

Sponsors & Collaborators

Principal Investigators

  • Robert D Newman, MD, MPH · U.S. Centers for Disease Control and Prevention

  • Laurence Slutsker, MD, MPH · U.S. Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Weeks
Max Age
16 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-03-31
Completion
2008-03-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111163 on ClinicalTrials.gov